The HCC Virtual Experts Knowledge share will address “Appropriate selection of patients for 1^st line monotherapy in advanced or unresectable HCC and treatment management in relation with AEs”. Chaired by Prof. Richard Finn, MD, (USA) and co-chaired by Dr Mohamed Bouattour (France) and James Harding, MD (USA).

The educational objectives for the meeting are:

• Explore the patient-profile who could benefit from VEGFR-TKI monotherapy 1^st line in advanced or unresectable HCC
• Interpret the real-world data and understand the implications for clinical practice
• Understand the safety profile of the monotherapies, be able to recognise the cause of toxicities and know the appropriate dosing strategies to manage side effects
• A look into the future, the potential of combination therapies in the treatment of HCC